MedTrace Logo

EARly Prevention of aTHeroma Progression

NCT02105623 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2018-06-25

No results posted yet for this study

Summary

The purpose of this study is to compare standard therapy (risk factor control, life style modification) versus standard therapy plus low-dose rosuvastatin therapy (5mg/day) on progression of coronary atherosclerosis in statin naive individuals who have mild CAD (nonobstructive coronary atherosclerotic plaques) and normal LDL (low-density lipoprotein) cholesterol levels(\<130mg/dl).

Conditions

  • Coronary Arteriosclerosis

Interventions

BEHAVIORAL

Standard Therapy

Risk factor control Diet Exercise for 24months

DRUG

Rosuvastatin

Risk factor control rosuvastatin 5mg/day for 24months

Sponsors & Collaborators

  • CardioVascular Research Foundation, Korea

    collaborator OTHER

  • CHEOL WHAN LEE, M.D., Ph.D

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02105623 on ClinicalTrials.gov